HUTCHMED jumps most in near 4 years on GSK licensing deal
03/09/2026 06:26
BUZZ-HUTCHMED jumps most in near 4 years on GSK licensing deal ** Shares of HUTCHMED (China) 0013.HK jump 16.5% to HK$22.3, set for the biggest one-day pct gain since November 2022
** HUTCHMED said on Thursday its unit had signed an exclusive development and licensing agreement with a subsidiary of GSK GSK.L to develop and commercialise its investigational cancer drug, HMPL-A830
** The agreement includes a $110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to $1.295 billion, and royalties on net sales - HUTCHMED
** YTD, stock up 4.8%, Hang Seng Biotech Index .HSBIO up 10.8%
(Reporting by Donny Kwok)
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation